tbuckley/cabot-search huggingface dataset:
Impact of variable fee schedule reimbursement (VFSR) on anti-emetic utilization and quality of care.
Authors: Maria Lopes, Sam Leo, Haita Makanji, Michael Polson, Yuqian Liu, Kristen M. Reimers, Todd Lord, Steve Cutts
Journal: Journal of Clinical Oncology (2016)

e18256 Background: Due to current payment models, reimbursement for 5-HT3 receptor antagonists (5-HT3-i’s) is largely driven by drug acquisition cost and differs significantly for the various products. A VFSR that normalizes reimbursement for all 5-HT3-i’s regardless of cost may affect physician drug choice by limiting financial bias, without sacrificing quality of care. Methods: A VFSR program that equalized physician reimbursement for branded palonosetron with alternative generic 5-HT3-i’s was implemented in July 2009 in a commercial health plan (2.3 million lives). A retrospective analysis of claims for physician office-administered 5-HT3-i’s for patients with a cancer diagnosis between 1/1/2008 and 9/30/2015 was performed to assess impact of VFSR on 5-HT3-i utilization. Additionally, claims were analyzed to assess impact on guideline recommended 5-HT3-i use in adult patients receiving moderate-risk (MEC) or high-risk emetogenic chemotherapy (HEC) in 2015 compared to 2008. Inappropriate use was defined as patients with a cancer diagnosis with a palonosetron claim without MEC or HEC within 0 to 3 days. Results: Prior to VFSR, palonosetron represented 78% of 5-HT3-i claims compared to 54% post-VFSR. The utilization shift led to an estimated annual cost-avoidance of $1,732,158. Between 1/1/15 and 9/30/15, of all adult patients receiving MEC, 78% had a claim for palonosetron within 3 days prior to MEC. Of all adult patients receiving HEC, 96% had a claim for any 5-HT3-i within 3 days prior. During the same time period in 2008, 85% and 98% of patients receiving MEC or HEC had a claim for palonosetron or a 5-HT3-i, respectively. The inappropriate use of palonosetron decreased from 519 claims in the 2008 period to 199 claims in 2015. Conclusions: After VFSR implementation, appropriate use of 5-HT3-i’s in patients receiving HEC remained stable, while use of palonosetron with MEC decreased slightly. Decline in total palonosetron use was largely driven by reduction in inappropriate use among cancer patients not receiving MEC or HEC. VFSR is an opportunity to remove financial bias from drug selection and can improve cost-effective anti-emetic care without restricting physician treatment options.
488P Overexpression of NK cell-activating ligand MICA/B correlates with superior outcomes and might be a therapeutic target for chemo-immunotherapy in non-small-cell lung cancer
Authors: R. Okita, T. Yukawa, Y. Nojima, A. Maeda, S. Saisho, K. Shimizu, M. Nakata
Journal: Annals of Oncology (2015)
Oncogenic correlates of epilepsy in glioblastoma.
Authors: Sharon Berendsen, Wim G.M. Spliet, Marjolein Geurts, Wim Van Hecke, Tatjana Seute, Tom J. Snijders, Erica Hlavin Bell, Arnab Chakravarti, Pierre A. Robe
Journal: Journal of Clinical Oncology (2016)

2057 Background: Epilepsy at presentation is a favorable prognostic factor in glioblastoma. In literature, deregulated expression of serum response factor (SRF) has been associated with epilepsy in animal models, and seems to enhance proliferation and invasion in multiple types of cancer. In this study, we analyze the biological mechanisms that associate with epilepsy in glioblastoma patients, and which might thus underlie this prognostic effect. Methods: Molecular classification, mRNA and miRNA expression-based (gene set) enrichment analyses were performed on fresh frozen tissue obtained from 76 tumors. Hospital records were screened for the presence of seizures at presentation of the disease. Protein expression patterns of gene set targets (ATRX, STAT5b) and markers of epithelial-mesenchymal transition (NF-κB, C/EBP-β and STAT3) were determined with immunohistochemistry on tissue microarrays containing 339 tumors. Results: Gene sets involved in hypoxia/HIF1-α, SRF, C/EBP-β and LPS-induced signaling pathways were significantly downregulated in glioblastoma patients who presented with epilepsy. On a protein level, epileptogenic tumors were characterized by a significant downregulation of phospho-STAT5b, a target of HIF1-α. No differential expression between patients with or without epilepsy was observed for ATRX, which is a target of SRF and has been associated with prognosis of glioma patients. Epilepsy status did not associate to EMT protein expression, molecular classification or miRNA expression. Conclusions: Epileptogenic GBMs show a downregulation of HIF-1α/STAT5b and SRF signaling compared to glioblastomas that do not present with epilepsy. These genes are known to play oncogenic roles in glioblastoma and other types of cancer, and SRF, which is deregulated in non-tumoral epileptic brain, might provide insight in the tumor’s epileptogenicity.
Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis
Authors: Ayodele Odutayo, Christopher X Wong, Allan J Hsiao, Sally Hopewell, Douglas G Altman, Connor A Emdin
Journal: BMJ (2016)

<b>Objective</b> To quantify the association between atrial fibrillation and cardiovascular disease, renal disease, and death. <b>Design</b> Systematic review and meta-analysis. <b>Data sources</b> Medline and Embase. <b>Eligibility criteria</b> Cohort studies examining the association between atrial fibrillation and cardiovascular disease, renal disease, and death. Two reviewers independently extracted study characteristics and the relative risk of outcomes associated with atrial fibrillation: specifically, all cause mortality, cardiovascular mortality, major cardiovascular events, any stroke, ischaemic stroke, haemorrhagic stroke, ischaemic heart disease, sudden cardiac death, congestive heart failure, chronic kidney disease, and peripheral arterial disease. Estimates were pooled with inverse variance weighted random effects meta-analysis. <b>Results</b> 104 eligible cohort studies involving 9 686 513 participants (587 867 with atrial fibrillation) were identified. Atrial fibrillation was associated with an increased risk of all cause mortality (relative risk 1.46, 95% confidence interval 1.39 to 1.54), cardiovascular mortality (2.03, 1.79 to 2.30), major cardiovascular events (1.96, 1.53 to 2.51), stroke (2.42, 2.17 to 2.71), ischaemic stroke (2.33, 1.84 to 2.94), ischaemic heart disease (1.61, 1.38 to 1.87), sudden cardiac death (1.88, 1.36 to 2.60), heart failure (4.99, 3.04 to 8.22), chronic kidney disease (1.64, 1.41 to 1.91), and peripheral arterial disease (1.31, 1.19 to 1.45) but not haemorrhagic stroke (2.00, 0.67 to 5.96). Among the outcomes examined, the highest absolute risk increase was for heart failure. Associations between atrial fibrillation and included outcomes were broadly consistent across subgroups and in sensitivity analyses. <b>Conclusions</b> Atrial fibrillation is associated with an increased risk of death and an increased risk of cardiovascular and renal disease. Interventions aimed at reducing outcomes beyond stroke are warranted in patients with atrial fibrillation.
Minimal Residual Disease and Mutational Status Prior to and after SCT for Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Authors: Heike Pfeifer, Sylvia Wystub, Barbara Wassmann, Patrick Brueck, Nicola Goekbuget, Hubert Serve, Dieter Hoelzer, Oliver G Ottmann
Journal: Blood (2008)
No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study
Authors: Ming-Chung Kuo, Tsai-Yun Chen, Ming-Chung Wang, Youngsen Yang, Su-Peng Yeh, Cheng-Shyong Chang, Yii-Jenq Lan, Chih-Cheng Chen, Yu-Chieh Su, Pei-Ching Hsiao, Ching-Yuan Kuo, Li-Yuan Bai, Wen-Li Hwang, Lee-Yung Shih
Journal: Blood (2014)
Polymorphism Of CD44 Influences Efficacy Of CD34+Cells Mobilization In Patients With Hematological Malignancies
Authors: Anna Szmigielska-Kaplon, Janusz Szemraj, Krzysztof Jamroziak, Agnieszka Pluta, Marta Robak, Anna Krawczynska, Katarzyna Hamara, Katarzyna Szmigielska, Tadeusz Robak, Agnieszka Wierzbowska
Journal: Blood (2013)
285O High dose (18 g/m2) versus low dose (12 g/m2) cytosine arabinoside as consolidation for acute myeloid leukemia: A phase 3 study: An interim analysis
Authors: P. Mehta, L. Kumar, V. Raina, A. Sharma, S. Bakhshi, A. Gogia, R.K. Sahoo, S. Pabbi, A. Chopra, R. Kumar
Journal: Annals of Oncology (2015)
a Randomized, Controlled, Prospective Study for Efficacy of Micafungin Versus Itraconazole As Empirical Antifungal Therapy for Febrile Neutropenic Patients with Acute Leukemia
Authors: Seong Hyun Jeong, Dae Young Kim, Jun Ho Jang, Yeung-Chul Mun, Sung-Hyun Kim, Chul Won Choi, Jin Seok Kim, Joon Seong Park
Journal: Blood (2014)
Metabolic Tumor Volume Has Potential Clinical Impact Compared with SUVmax in Primary Gastrointestinal Diffuse Large B Cell lymphoma
Authors: Moo-Kon Song, Joo-seop Chung, Ho-Jin Shin, Joon Ho Moon, Jeong Ok Lee, Ho Sup Lee, Sang-Min Lee, Gyeong Won Lee, Suee Lee
Journal: Blood (2011)
Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
Authors: F Van De Werf, R Diaz, E Paolasso
Journal: Circulation (1994)

BACKGROUND Aspirin, by nonselectively blocking cyclooxygenase both in platelets and in endothelial cells, not only inhibits the thromboxane A2 pathway of platelet activation but at the same time also the generation of vasodilating and platelet-inhibitory prostanoids, such as prostacyclin, by the endothelial cells. Ridogrel, by inhibiting thromboxane A2 synthase and blocking the thromboxane A2/prostaglandin endoperoxide receptors, is a more potent antiplatelet agent than aspirin and might offer an advantage over aspirin as an adjunct to thrombolysis. This study was performed to compare the efficacy and safety of ridogrel with that of aspirin as conjunctive therapy for thrombolysis in patients with acute myocardial infarction. METHODS AND RESULTS A total of 907 patients with acute myocardial infarction were randomized between aspirin and ridogrel given in addition to streptokinase (1.5 MU over a period of 1 hour). The primary end point was coronary patency (TIMI flow grades 2 and 3) at predischarge angiography to be performed between 7 and 14 days after admission. A patent infarct-related vessel was found in similar proportions of patients in the two treatment groups: 72.2% in the ridogrel and 75.5% in the aspirin group. The presence of clinical markers of reperfusion at 2 hours and the incidence of major clinical events during hospital stay were also similar in both groups. However, in a post hoc analysis, a lower incidence of new ischemic events (reinfarction, recurrent angina, ischemic stroke) was observed with ridogrel: 13% versus 19% in the aspirin group (a 32% reduction; P &lt; .025). No excess of serious bleeding complications, including hemorrhagic stroke, was found. CONCLUSIONS Ridogrel is not superior to aspirin in enhancing the fibrinolytic efficacy of streptokinase but might be more effective in preventing new ischemic events.
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group
Authors: Gabor Kovacs, Sandra Robrecht, Anna Maria Fink, Jasmin Bahlo, Paula Cramer, Julia von Tresckow, Christian Maurer, Petra Langerbeins, Günter Fingerle-Rowson, Matthias Ritgen, Michael Kneba, Hartmut Döhner, Stephan Stilgenbauer, Wolfram Klapper, Clemens-Martin Wendtner, Kirsten Fischer, Michael Hallek, Barbara Eichhorst, Sebastian Böttcher
Journal: Journal of Clinical Oncology (2016)

Purpose To determine the value of minimal residual disease (MRD) assessments, together with the evaluation of clinical response in chronic lymphocytic leukemia according to the 2008 International Workshop on Chronic Lymphocytic Leukemia criteria. Patients and Methods Progression-free survival (PFS) and overall survival of 554 patients from two randomized trials of the German CLL Study Group (CLL8: fludarabine and cyclophosphamide [FC] v FC plus rituximab; CLL10: FC plus rituximab v bendamustine plus rituximab) were analyzed according to MRD assessed in peripheral blood at a threshold of 10-4 and clinical response. The prognostic value of different parameters defining a partial response (PR) was further investigated. Results Patients with MRD-negative complete remission (CR), MRD-negative PR, MRD-positive CR, and MRD-positive PR experienced a median PFS from a landmark at end of treatment of 61 months, 54 months, 35 months, and 21 months, respectively. PFS did not differ significantly between MRD-negative CR and MRD-negative PR; however, PFS was longer for MRD-negative PR than for MRD-positive CR ( P = .048) and for MRD-positive CR compared with MRD-positive PR ( P = .002). Compared with MRD-negative CR, only patients with MRD-positive PR had a significantly shorter overall survival (not reached v 72 months; P = .001), whereas there was no detectable difference for patients with MRD-negative PR or MRD-positive CR ( P = 0.612 and P = 0.853, respectively). Patients with MRD-negative PR who presented with residual splenomegaly had only a similar PFS (63 months) compared with patients with MRD-negative CR (61 months; P = .354), whereas patients with MRD-negative PR with lymphadenopathy showed a shorter PFS (31 months; P < .001). Conclusion MRD quantification allows for improved PFS prediction in both patients who achive PR and CR, which thus supports its application in all responders. In contrast to residual lymphadenopathy, persisting splenomegaly does not impact outcome in patients with MRD-negative PR.
Geriatric periodontology: how the need to care for the aging population can influence the future of the dental profession
Authors: Ira B. Lamster
Journal: Periodontology 2000 (2016)

Abstract The world's population is aging, and it has been estimated that by 2050, the number of people 65 years of age and older will reach 1.5 billion. The aging population will be affected by noncommunicable chronic diseases, including diabetes mellitus, cardiovascular disease and cognitive impairment. This important demographic shift includes a reduction in tooth loss/edentulism, particularly in older adults of the developed countries in North America, western Europe and north‐east Asia. Therefore, in the future, dental providers will be required to care for an expanded number of older adults who have retained teeth and are medically complex. As the linkage of oral disease and systemic disease has focused on the relationship of periodontitis and noncommunicable chronic diseases, a broad review of ‘geriatric periodontology’ is both timely and important. This volume of Periodontology 2000 covers a range of subjects under this heading. Included are the demographics of an aging world; the effect of aging on stem cell function in the periodontium; the periodontal microbiota associated with aging; the host response in the periodontium of aging individuals; an analysis of the prevalence of periodontitis in the USA on a national, state‐wide and community basis; differentiation of physiologic oral aging from disease; treatment of periodontal disease in older adults; implant therapy for older patients; oral disease and the frailty syndrome; the relationship of tooth loss to longevity and life expectancy; and the relationship of periodontal disease to noncommunicable chronic diseases. Although ‘geriatric dentistry’ is not a recognized specialty in dentistry, and ‘geriatric periodontology’ is a descriptive title, the subject of this volume of Periodontology 2000 is critical to the future of clinical dentistry, dental public health and dental research. Any comprehensive focus on older patients can only be accomplished with an emphasis on interprofessional education and practice. If embraced, this shift will allow the dental profession to be more closely aligned with the larger health‐care environment, and can improve both oral health and health outcomes for patients seen in the dental office.
P1056 : Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in patients with nonalcoholic fatty liver disease, independently of diabetes, hypertension and dyslipidemia
Authors: E. Vanni, L. Mezzabotta, R. Faletti, M. Morello, A. Marengo, G. Battisti, S. Frea, M. Cannillo, E. Mosso, C. Rosso, L. Bergamasco, A. Gastaldelli, M. Rizzetto, E. Bugianesi
Journal: Journal of Hepatology (2015)
Remission Induction Treatment for 6 Patients of Jehovah’s Witnesses with De Novo Acute Leukemia.
Authors: Hiroyuki Fujita, Mai Iguchi, Takayoshi Tachibana, Sachiya Takemura, Jun Taguchi, Masatsugu Tanaka, Atsuo Maruta, Yoshiaki Ishigatsubo
Journal: Blood (2006)
Erratum to: A survey of best practices for RNA-seq data analysis
Authors: Ana Conesa, Pedro Madrigal, Sonia Tarazona, David Gomez-Cabrero, Alejandra Cervera, Andrew McPherson, Michal Wojciech Szcześniak, Daniel J. Gaffney, Laura L. Elo, Xuegong Zhang, Ali Mortazavi
Journal: Genome biology (2016)

During editing of the article by Conesa et al. [1], an error was introduced to some of the citations, such that incorrect references were provided for some articles the second time they were cited.The following sentences are affected: Algorithms that quantify expression from transcriptome mappings include RSEM (RNA-Seq by Expectation Maximization) [40], eXpress [41], Sailfish [35] and kallisto [42] among others.These methods allocate multi-mapping reads among transcript and output within-sample normalized values corrected for sequencing biases [35, 41, 43].The citation for Sailfish should be [34] (Patro et al., Nat Biotechnol.2014;32:463-4) in both sentences.Additional factors that interfere with intra-sample comparisons include changes in transcript length across samples or conditions [50], positional biases in coverage along the transcript (which are accounted for in Cufflinks), average fragment size [43], and the GC contents of genes (corrected in the EDAseq package [21]).The citation for EDAseq should be [20] (Risso et al.
Accelerating bioelectric functional development of neural stem cells by graphene coupling: Implications for neural interfacing with conductive materials
Authors: Rongrong Guo, Shasha Zhang, Miao Xiao, Fuping Qian, Zuhong He, Dan Li, Xiaoli Zhang, Huawei Li, Xiaowei Yang, Ming Wang, Renjie Chai, Mingliang Tang
Journal: Biomaterials (2016)
Cough and haemoptysis in an older woman
Authors: Joseph Dalby Sinnott, David C Howlett
Journal: BMJ (2016)

A 72 year old woman was referred to the respiratory clinic with a recent history of cough and haemoptysis. She had no history of smoking or weight loss. What does this plain chest radiograph show (fig 1)?



Fig 1 

A pulmonary fungal ball within the …
Implications of Thiamine Fortification in Cambodian Fish Sauce
Authors: Melissa Wake, Bruce Neal
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
IMCT-14AN UPDATE ON IPILIMUMAB AND BEVACIZUMAB IN GLIOBLASTOMA
Authors: Paul Mulholland, Thomas Carter, Kerry Chester, Heather Shaw
Journal: Neuro-Oncology (2015)

BACKGROUND: Median survival in glioblastoma is less than one year. We have previously reported a series of six patients treated with the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in combination with the anti-VEGF mAb bevacizumab. Our preliminary results showed promising anti-tumor activity and an acceptable toxicity profile. METHODS: In a continuation of this single practice case series, 20 patients were consented for and treated with ipilimumab and bevacizumab in combination. Safety, tolerability and response to treatment were reviewed for all patients. RESULTS: 19 poor-prognosis patients with glioblastoma (WHO Grade IV), and 1 with a glioneuronal tumor were treated; 6 patients following palliative (chemo)radiation and 14 patients with recurrent disease. Median age at start of treatment was 47 (range 23-69). Ipilimumab was dosed at 3mg/kg and all patients received concurrent GM-CSF. Bevacizumab was dosed at 10mg/kg every two weeks. 65% of patients completed 4 cycles of standard 3-weekly ipilimumab therapy. First evaluation MRI scans are available for 19 patients; 26% showed partial response (3 patients had >90% response), 48% had stable disease and 26% progressed. Toxicity seen was as follows; grade 3 abscess (3 patients), grade 2 diarrhea (3 patients), grade 3 rash (1 patient), grade 2 rash (1 patient), grade 2 perianal fistula (1 patient) and grade 2 arthritis (1 patient). Autoimmune toxicity was manageable with systemic corticosteroid therapy. Response and toxicity data continues to be evaluated for all patients. CONCLUSIONS: This combination therapy shows promising activity with a predictable and manageable toxicity profile. Further studies are warranted.
Cosmetic surgery will be regulated more closely in England
Authors: Adrian O’Dowd
Journal: BMJ (2016)

Clinics that provide cosmetic surgery are to come under closer scrutiny and be rated in the same way as GPs and hospitals, under new government plans.

The Department of Health for England launched a two month consultation on 22 August,1 proposing to extend the types of healthcare provider registered with the main NHS regulator the Care Quality Commission that it is able to rate after inspection.

Under the proposals, the CQC would expand its rating programme to include up to another 1000 providers. These would include cosmetic surgery providers, services for pregnancy termination, substance misuse centres, refractive eye surgery providers, independent community health providers, independent ambulance services, and independent …